Notícias Johnson and Johnson - JNJ | Ações New York Stock Exchange | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NYSE
Johnson and Johnson (JNJ)
Johnson and Johnson (JNJ) Notícias

Johnson and Johnson (JNJ)

144,47

0,89

(0,62%)

Fechado 21 Dezembro 6:00PM

Atrasado por 15 minutos

144,70

0,23

(0,16%)

Após o horário de negociação: 9:57PM

Atrasado por 15 minutos

Discussões em tempo real e ideias de negociação: Negocie com confiança com nossa poderosa plataforma.

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study

Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma

TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma

Form 144 - Report of proposed sale of securities

Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab)

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Johnson and Johnson

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições